ArticleCell biology and toxicology2026
Post-transcriptional activation of TGF-β signaling via SMAD mRNA stabilization by EIF4A3 promotes EMT and metastasis in gastric cancer.
Article in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anticancer Effects of Fluphenazine Alone and in Combination with Cisplatin in Gastric Cancer Cells and a Mouse Xenograft Model.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is characterized by high mortality due to late-stage diagnosis and aggressive metastatic behavior. Epithelial-mesenchymal transition (EMT), primarily driven by the TGF-β/SMAD signaling, critically contributes to GC progression. However, the molecular mechanisms regulating this pathway remain incompletely understood.
methodsWe investigated the expression, function, and regulatory mechanisms of EIF4A3 in GC using patient tissues, GC cell lines, and in vivo mouse models. We performed loss-of-function experiments and xenograft studies to assess the biological effects of EIF4A3. Mechanistic studies were applied for exploring the relation between EIF4A3 and TGF-β/SMAD signaling.
resultsEIF4A3 upregulation was observed in GC samples as well as cell lines compared to normal counterparts, and indicated advanced clinical stages and poor clinical outcomes. EIF4A3 knockdown markedly repressed GC cell growth and DNA synthesis in vitro, while restraining tumor growth and Ki67 expression in xenograft models. Silencing EIF4A3 impaired cell migration, invasion, and lung metastasis, and reversed TGF-β induced EMT marker expression. Mechanistically, TGF-β1 transcriptionally induced EIF4A3 via SMAD2/3 binding to its promoter. In turn, EIF4A3 enhanced TGF-β/SMAD signaling by directly binding to and stabilizing SMAD2, SMAD3, and SMAD4 mRNAs, prolonging their half-lives and promoting their phosphorylation and nuclear accumulation. Furthermore, EIF4A3 knockdown reduced SMAD2/3 phosphorylation, nuclear translocation, and downstream EMT marker expression, thereby attenuating the pro-metastatic effects of TGF-β signaling.
conclusionsOur study identifies EIF4A3 as a critical post-transcriptional regulator and downstream effector of the TGF-β/SMAD pathway. EIF4A3 forms a positive feedback loop with TGF-β/SMAD signaling, thereby reinforcing EMT and promoting metastatic progression in GC. These findings establish EIF4A3 as a novel post-transcriptional amplifier of TGF-β signaling and a promising candidate for diagnostic and therapeutic intervention in metastatic GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.